Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: The Children's Oncology Group

Journal of Clinical Oncology

Volumn 25, Issue 12, 2007, Pages 1505-1511

  Malempati, Suman ^a   Nicholson, H Stacy ^a   Reid, Joel M ^a   Blaney, Susan M ^a   Ingle, Ashish M ^a   Krailo, Mark ^a   Stork, Linda C ^a   Melemed, Allen S ^a   McGovern, Renee ^a   Safgren, Stephanie ^a   Ames, Matthew M ^a   Adamson, Peter C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; DRUG DERIVATIVE; FOLIC ACID ANTAGONIST; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADOLESCENT; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG ERUPTION; DRUG HALF LIFE; FEMALE; FEVER; GRANULOCYTE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFANT; INFECTION; LEUKOCYTE; LYMPHOCYTOPENIA; MALE; NAUSEA; NEUTROPENIA; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; DRUG ADMINISTRATION; DRUG RESISTANCE; FOLLOW UP; HOSPITAL; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; NEOPLASM; ONCOLOGY; PATHOLOGY; PRESCHOOL CHILD; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLIC ACID ANTAGONISTS; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HOSPITALS, PEDIATRIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MEDICAL ONCOLOGY; NEOPLASM STAGING; NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34248227619     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.1694     Document Type: Article

References (51)

1. Adjei AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10:4276s-4280s, 2004
2. Jones RJ, Twelves CJ: Pemetrexed: A multitargeted antifolate (ALIMTA, LY-231514). Expert Rev Anticancer Ther 2:13-22, 2002
3. Shih C, Chen VJ, Gossett LS, etal: LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123, 1997
4. Mendelsohn LG, Shih C, Chen VJ, et al: Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-47, 1999
5. Zhao R, Babani S, Gao F, et al: The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate. Clin Cancer Res 6:3687-3695, 2000
6. Chen VJ, Bewley JR, Andis SL, et al: Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 78:27-34, 1998 (suppl 3)
7. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999
8. Schultz RM, Patel VF, Worzalla JF, et al: Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 19:437-443, 1999
9. Kindler HL: The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer 95:928-932, 2002
10. Mauceri HJ, Seetharam S, Salloum RM, et al: Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. Int J Oncol 19:833-835, 2001
11. Raymond E, Louvet C, Tournigand C, et al: Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int J Oncol 21:361-367, 2002
12. Teicher BA, Chen V, Shih C, et al: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016-1023, 2000
13. Giovannetti E, Mey V, Nannizzi S, et al: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110-118, 2005
14. Giovannetti E, Mey V, Danesi R, et al: Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936-2943, 2004
15. Fossella FV, Gatzemeier U: Phase I trials of pemetrexed. Semin Oncol 29:8-16, 2002
16. Boyer MJ, Rivory LP, Clarke SJ: Pemetrexed: Single-agent and combination phase I study overview. Semin Oncol 29:18-23, 2002
17. Calvert H: Folate status and the safety profile of antifolates. Semin Oncol 29:3-7, 2002
18. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
19. Dittrich C, Petruzelka L, Vodvarka P, et al: A phase I study of pemetrexed (Alimta) and cyclophosphamide in patients with locally advance or metastatic breast cancer. Clin Cancer Res 12:7071-7078, 2006
20. Nakagawa K, Kudoh S, Matsui K, et al: A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677-682, 2006
21. Spielmann M, Martin M, Namer M, et al: Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: An interim analysis. Clin Breast Cancer 2:47-51, 2001
22. Clarke SJ, Abratt R, Goedhals L, et al: Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13:737-741, 2002
23. Pivot X, Raymond E, Laguerre B, et al: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649-655, 2001
24. Scagliotti GV, Shin DM, Kindler HL, et al: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556-1561, 2003
25. Shepherd FA, Dancey J, Arnold A, et al: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595-600, 2001
26. Manegold C, Gatzemeier U, von Pawel J, et al: Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed di-sodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000
27. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003
28. Cohen MH, Johnson JR, Wang YC, et al: FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368, 2005
29. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
30. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
31. Chaudhary AK, Knadler MP, Lantz R, et al: Analysis of LY231514 by LC/MS/MS. Proceedings of the 47th ASMS Conference on Mass Spectrometry Allied Topics, Dallas, TX, June 1999
32. Hanauske AR, Chen V, Paoletti P, et al: Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors. Oncologist 6:363-373, 2001
33. Zinner RG, Fossella FV, Gladish GW, et al: Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104:2449-2456, 2005
34. O'Shaughnessy JA, Clark RS, Blum JL, et al: Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6:143-149, 2005
35. Ma CX, Nair S, Thomas S, et al: Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23:5929-5937, 2005
36. Worzalla JF, Shih C, Schultz RM: Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res 18:3235-3239, 1998
37. Adjei AA: Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5:S51-S55, 2004 (suppl 2)
38. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380, 1999
39. Rivory LP, Clarke SJ, Boyer M, et al: Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 765:135-140, 2001
40. Flintoff WF, Sadlish H, Gorlick R, et al: Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 1690:110-117, 2004
41. Zhao R, Hanscom M, Chattopadhyay S, et al: Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: Association with the presence of a secondary transport pathway. Cancer Res 64:3313-3319, 2004
42. Zhao R, Zhang S, Hanscom M, et al: Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 11:1294-1301, 2005
43. Balis FM, Patel R, Luks E, et al: Pediatric phase I trial and pharmacokinetic study of trimetrexate. Cancer Res 47:4973-4976, 1987
44. Pappo AS, Vats T, Williams TE, et al: Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 21:280-282, 1993
45. Adamson PC, Balis FM, Miser J, et al: Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res 50:4464-4467, 1990
46. Adamson PC, Balis FM, Miser J, et al: Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res 52: 521-524, 1992
47. Horton TM, Blaney SM, Langevin AM, et al: Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: A Pediatric Oncology Group study. Clin Cancer Res 11:1884-1889, 2005
48. Widemann BC, Balis FM, Godwin KS, et al: The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model. Cancer Chemother Pharmacol 44:439-443, 1999
49. Ratliff AF, Wilson J, Hum M, et al: Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458-1464, 1998
50. Pappo A, Dubowy R, Ravindranath Y, et al: Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Natl Cancer Inst 82:1641-1642, 1990
51. Cole PD, Drachtman RA, Smith AK, et al: Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089-8096, 2005